Data modelling and analytics - Primary Care Prescribing and Primary Care Prescribing Impact on Secondary Care activity

Neo Health Hub Limited · Commercial

Expired The latest version ended on 13 February 2026. The September 2026 register still lists the agreement, but its term has passed.

Reference: DARS-NIC-692602-Q6P4F
Latest version: v4.4
Term of latest version: 14 February 2025 to 13 February 2026
Start date: 15 January 2024
Data controller: Sole Data Controller
Commercial purposes: Yes
Sublicensing: No
Files released to date: 0

Why the data was released

Objective for processing

Neo Health Hub Limited requires access to NHS England for the purpose of providing the following services to clients in the health sector:

• Online tools and services – management information, analysis and clinical benchmarking, and consultancy;

• Bespoke analytics – customised projects to meet individual needs;

• Research for publication – thought leadership in the field of healthcare data analytics, with the aim of improving the planning, delivery and outcome of health and social care.

We believe that these offerings utilising both the Patient Level Prescribing Data and linked HES will provide a unique solution for the NHS and non NHS organisations.

NHS clients access analysis of the data to:

• Review prescribing trends and the association to secondary care performance measures.

• Track and trend performance, identify areas for efficiency savings and understand and influence demand and patient flow throughout the health and care system.

• Investigate risk-adjusted quality, patient safety and clinical outcomes data, benchmark against other healthcare organisations and to help improve the quality of patient care and identify areas for improvement.

All of the above will be in relation to the Primary Care Prescribing cohorts developed from the linked medicines dispensed in primary care data.

The Data will be used to provide services to the following types of clients only:

• NHS Trusts

• Integrated Care Systems

• Integrated Care Boards

• Commissioning Support Units

• Department of Health and Social Care

• NHS England

• UK Health Security Agency and Office for Health Improvement and Disparities

• National Institute for Health and Care Excellence

Neo Health Hub Limited will also work with:

• Non-NHS organisations providing services to benefit the NHS - these are only supplied with aggregate, small-number suppressed analyses in line with the HES analysis guide.

• Non-NHS organisations to benefit public health and social care - these are only supplied with aggregate, small-number suppressed analyses where benefits can be identified for the health and social care system. Algorithms or coefficients that have been derived through research on HES data may be provided directly to a customer for implementation on their own local data. Data provided in all outputs to non-NHS organisations will be at an aggregate level and small number suppression will be implemented in line with HES analysis guidelines.

The Data will be used to provide the following services only:

• Variations in health outcomes in the context of primary care prescribing

• Health inequalities and needs analysis in the context of primary care prescribing

• Predictions

• Performance data and changes in clinical practice and prescribing

• Efficiency monitoring

• Benchmarking

• Activity monitoring

• National target performance

• Practice performance monitoring

• Capacity and utilisation management

• Patient segmentation analysis

• Overall data quality

BACKGROUND:

Neo Health Hub Limited utilizes expert pharmaceutical domain expertise to meet data modelling & analytic needs throughout the healthpital feedback services development to produce tools and reports used by health and social care. Data from NHS England is required to achieve the following fundamental aims:

1. Comprehension and quantification of the prescribing trends across NHS England primary Care.

2. Through robust research, to not only add to the body of healthcare knowledge but reveal key prescribing trends and patterns over time in NHS prescribing activity.

3. Application of data to identify key prescribing improvements in terms of the alignment to national benchmarks and consistency of prescribing.

4. Provide solutions to support commissioning, analytical support, and outcomes analytics for NHS organisations, ranging from NHS England to regional teams.

5. Provide services to commercial organisations within life sciences, social care, charities and healthcare providers who will use the outputs and insights provided by Neo Health Hub Limited to work collaboratively with NHS organisations to promote health and improve well-being of patients, leading to more patient centric services.

The intention of the processing is to:

· Achieve widespread benefits to healthcare, including changes to patient care, reduced cost burden and uptake and monitoring of current health policies.

· Provide analysis to decision making bodies in order to enable them to grant patients access to innovative medicines that potentially reduce cost and activity burden within the national health economies across England.

· Contribution of the already existing knowledge within the medical community to ignite further research into improving patient care.

NeoHealthHub Limited requires access to NHS England data for the purpose of providing services to the NHS, healthcare charity organisations and NeoHealthHub Limited's private organisation clients in the health sector. The data will be used to provide services to the following types of clients only:

• NHS Trusts

• Integrated Care Systems/Boards (ICSs/ICBs)

• Sustainability and Transformation Partnerships (STPs)

• Primacy Care Teams (including GPs / Nurses)

• Pharmaceutical companies

• Medical Device companies

Having spoken to members of the NHS regarding their expected usage, it is anticipated that members of medicines optimisation teams and PCN pharmacists will have primary access to the dashboard who will in turn promote its use to members of prescribing accounts to review information they will find of interest or are required to act upon. Due to the project specific access granted to the pharmaceutical industry and the broad nature of access for the NHS, the expected unique user volumes are 70% NHS and 30% pharmaceutical industry.

Expected User Type – Private

Initial Reviews will be undertaken to reach an approval of the client company. Successful access applicants will be companies that are able to demonstrate that they already undertake non promotional activities for the benefit of the NHS.

Post this approval being granted, the user types for the company will be reviewed. These users will be those that can demonstrate a direct relation to those non promotional activities which enabled the companies to be approved initially. We will also reserve the ability for select users that are directly linked to research and development or health economics outcomes research to be granted access for non-promotional purposes. Private company user access will be proactively limited, and this will be documented within the agreements signed by private companies with NeoHealthHub Limited.

Expected User Type – NHS

INTERVIEWS

NeoHealthHub Limited has undertaken several interviews with members of the NHS for the purpose of understanding their need for the service NeoHealthHub Limited aim to provide. Further details on perceived benefit on each interview are described in section 5d. Questions on these interviews included -

• What therapy areas would be of interest to receive further analysis on ?

• How they would use this information?

• How the information would be used to benefit the health and social care sector?

• How the information would benefit the patients within the health and social care sector?

The interviewees flagged that the best delivery formats for the analysis would be:

• A secure web based dashboard for each therapy area

• An annual report for each therapy area that showcases headlines of the dashboard

NeoHealthHub Limited agreed with the interviewees that the therapy areas with the broadest potential benefit for the analysis would be:

• Asthma and COPD (respiratory)

• Diabetes

• Heart Failure

• Insomnia (with a focus on addictive medicines)

Although the focus will remain on the above areas, NeoHealthHub will remain reactive to NHS priorities with potential analysis in other areas, for example:

HRT therapy, Opioids, Anti Depressants & Obesity.

Unlimited access will be granted to any user from the NHS or a registered healthcare charity free of charge.

NeoHealthHub Limited will charge all private sector organisations who request access to the outputs. A sustainable percentage of the profits from these sales will be allocated to further development of the dashboard to provide analysis pertaining to direct requests received from NHS users.

Any private sector access will be limited to those agreeing that any use of the data must be in line with it being used solely for projects that will benefit the health and social care sector and must not be in any way used to promote or market their products. It is expected that the predominant use of the data will be as an added benefit that the pharmaceutical company are investing in to make available.

The following NHS England Data will be accessed:

Medicines dispensed in Primary Care (NHSBSA data) – necessary to provide information including what types of medication are being prescribed to patients nationally, as well as their frequency. The data will provide the relevant indicators required to build resources aimed at supporting medicine optimisation.

Linked Medicines dispensed in Primary Care (NHSBSA data) – the core aspect of this application is to provide insights in the form of hospital activity relating to prescribing variations in primary care. The Medicines dispensed in primary care data will bring all of the other data sets together to enable to creation of patient prescribing profiles that will then be assessed in relation to hospital activity.

- Hospital Episode Statistics

Admitted Patient Care – due to the nature of the analysis combining primary care prescribing data and HES data, the predominant focus will be on chronic care. This is a significant proportion of the patients that are admitted into hospital and will provide significant context to the prescribing patterns in primary care and the impact it has on patients being admitted into hospital.

Emergency Care Dataset– many chronic illnesses result in acute ailments, for example diabetes and stroke. Understanding the accident and emergency attendances and the nature of these attendances will give further insightful context to the other data within this application

Outpatients- patients with chronic illness will have consistent follow ups and referrals into hospital. The Outpatient HES publication will provide information that will showcase the overall volume of these attendances to be able to provide comparable context geographical and between prescribing profiles.

The level of the data will be pseudonymised.

The data will be minimised as follows:

• Limited to 6 full years of data at any one time

• Limited to data fields which are necessary to deliver products and services that benefit health and care in the UK

Neo Health Hub Limited is the controller as the organisation responsible for ensuring that the data will only be processed for the purposes described above.

The lawful basis for processing personal data under the UK GDPR is:

Article 6(1)(f) - processing is necessary for the purposes of the legitimate interests pursued by the controller. NeoHealthHub Limited has determined the processing is necessary for its legitimate interests in being able to provide tools and services that will benefit healthcare organisations. NeoHealthHub Limited will use the data to provide commercial services to healthcare providers to enable improved healthcare delivery through identification of more effective medicines.

The lawful basis for processing special category data under the UK GDPR is:

Article 9(2)(h) - processing is necessary for the purposes of preventive or occupational medicine, for the assessment of the working capacity of the employee, medical diagnosis, the provision of health or social care or treatment or the management of health or social care systems and services on the basis of Union or Member State law or pursuant to contract with a health professional and subject to the conditions and safeguards referred to in paragraph 3; Personal data referred to in paragraph 1 may be processed for the purposes referred to in point (h) of paragraph 2 when those data are processed by or under the responsibility of a professional subject to the obligation of professional secrecy under Union or Member State law or rules established by national competent bodies or by another person also subject to an obligation of secrecy under Union or Member State law or rules established by national competent bodies.

This processing is necessary for scientific research purposes in accordance with Article 89(1) UK General Data Protection Regulation and Section 19(4)(b)(ii) UK Data Protection Act 2018, which shall be proportionate to the aim pursued, respect the essence of the right to data protection and provide for suitable and specific measures to safeguard the fundamental rights and the interests of the data subject, as provided for under this agreement.

The funding is provided by NeoHealthHub. The funding is specifically for the project described. There is no set end date for the funding at this stage.

Processing activities

No data will flow to NHS England for the purposes of this Agreement.

NHS England data will provide the relevant records from the Medicines dispensed in Primary Care (NHSBSA data), records from the Hospital Episode Statistics Admitted Patient Care, Emergency Care Dataset, and Outpatients datasets to NeoHealthHub Limited via the NHS England Secure Data Environment (SDE). The data will contain no direct identifying data items. The data will be pseudonymised and individuals cannot be reidentified through linkage with other data in the possession of the recipient. There are no further flows of data.

Neo Health Hub Limited will utilise medicines dispensed in primary care data to produce dashboards, reports and studies based on aggregated, suppressed, non-sensitive and non-identifiable data with the aim of answering and supporting the following points:

· Awareness of prescribing inequalities

· Awareness of prescribing efficiencies

· improve patient safety by contributing to safer and more effective prescribing - for example, it can be linked to maternity and child health data to study the effect of medicines given during pregnancy.

· enable research and support clinical trials into the medicines used by patients.

· inform planning and assist in monitoring national priorities like anti-microbial resistance

· improve services by helping to measure the uptake and effectiveness of new medicines

· There will also be a distinct focus on prescribing trends per and post the COVID-19 pandemic.

The Data will not be transferred to any other location.

The Data will be stored on servers at NHS England via the SDE.

The Data will be accessed by authorised personnel via remote access.

The Controller(s) must confirm and provide evidence upon audit by NHS England that access via any remote device complies with the data security obligations within this DSA and the Data Sharing Framework Contract.

For remote access:

- Remote access will only be from secure locations situated within the territory of use (as further restricted elsewhere within the DSA if so done) stated within this DSA;

- Access controls granting users the minimum level of access required are in place;

- Remote access is only via secure connections (e.g., VPNs or secure protocols) to protect data;

- Multifactor authentication (MFA) is required for remote access;

- Device security, including up-to-date software and operating systems, antivirus software, and enabled firewalls are utilised for the remote access;

- All remote access is undertaken within the scope of the organisation’s DSPT (or other security arrangements as per this DSA) and complies with the organisation’s remote access policy.

The above applies in addition to any condition set out elsewhere within the DSA (e.g. who may carry out processing, and for what purpose).

Remote processing will be from secure locations within: England. The data will not leave: England at any time.

Access is restricted to employees of NeoHealthHub Limited who have authorisation from the Managing Director.

All personnel accessing the data have been appropriately trained in data protection and confidentiality.

The data will not be linked with any other data.

There will be no requirement and no attempt to reidentify individuals when using the data.

Analysts from the NeoHealthHub Limited will process the data for the purposes described above.

NHS England’s Controlled Environment is a data storage and access platform that enables approved users to access de-identified data and analytical tools for approved projects. Users must identify themselves via a multi-factor authentication mechanism and are only able to access the datasets detailed within this agreement. Users can request that aggregated outputs are exported from the system following approval by trained NHSE staff. The access and use of the system is fully auditable, and all users must comply with the use of the data as specified in this agreement.

When processing data for insights and analysis NeoHealthHub Limited will ensure all reports before submission to end user are aggregated and small number double suppressed format in-line with NHS England's analysis guide.

As per data sharing agreement, all content will fully comply to Data Sharing Agreement between Neo Health Hub Limited and NHS England.

· Disease burden analysis: Present users with descriptive reports on current disease burden by identifying a cohort of patients and assessing the prescribing resource utilisation to better understand the particular disease type within a primary care setting, and target patient group based on real world data.

· Prescribing trend analysis: Present users with views of prescribing pathways for the treatment of specific therapy areas. This will allow further interrogation into the causes of variant in patient prescribing pathways and subsequent impact on polypharmacy, costs and hospital activity.

· Prescribing burden analysis: present users with views of prescribing volumes per patient · Prescribing and medicines safety issues that have arisen due to the COVID pandemic: Neo Health Hub Limited will produce indicators on changes in prescribing that have resulted from COVID allowing commissioners and healthcare professionals to identify and review any issues.

Expected output

The expected outputs of the processing will be:

• Monthly updated dashboards accessed by the NHS selected Charities and vetted private sector employees.

• Annual therapy area reports showcasing headlines from the dashboards developed

• Aggregated data tabulation provision in combination to retrospective studies.

The outputs will not contain NHS England data and will only contain aggregated information with small numbers suppressed as appropriate in line with the relevant disclosure rules for the dataset(s) from which the information was derived.

In June 2024 NeoHealthHub Limited launched its first Free to access for the NHS online dashboard focused on providing patient level analysis for prescribing patterns in the respiratory therapy area.

In July 2024 NeaHealthHub Limited launched its second free to access for the NHS online dashboard focused on providing patient level analysis for prescribing patterns for Insomnia.

52 NHS personnel have now registered for access to these dashboards. NeoHealthHub Limited have committed to maintaining the alignment of these dashboards to NHS requirements by collating monthly feedback submissions for requested enhancements and evolutions.

NeoHealthHub Limited have committed 240 hours per annum for bespoke NHS analytics across both data sharing agreements. Bespoke NHS requirements will be proactively sought out and provided on a first come first served basis. However, if multiple requests are received simultaneously, NeoHealthHub Limited will determine the order of delivery based upon the internally perceived level of benefit from the analysis. NeoHealthHub Limited reserve the right to provide more hours than committed for additional projects.

To date NeoHealthHub Limited have been approached by:

Kings College London and Menopause UK to utilise the data in a publication titled 'Understanding Cardiovascular Risk in High-Risk Women: exploring new opportunities to improve outcomes with menopause hormone therapy'. This project is ongoing and will conclude June 2025. Research will contribute to improving health equity by:

1. Highlighting inequities in menopause hormone therapy (MHT) prescribing

2. Exploring reasons for differences in MHT prescribing for underserved women

Linking the medicines dispensed in primary care data product to records from the Hospital Episode Statistics Admitted Patient Care, Emergency Care Dataset, and Outpatients datasets will enable all of our current services to be expanded to showcase more than just prescribing change outcomes and significantly increase the understanding of association, correlation and potential causation of outcomes in patients predominantly treated in primary care. An example proposal is to review the significant analysis already undertaken for SABA inhaler overuse and directly align the Asthma admissions data to those patients with consistent SABA inhaler overuse in comparison to those treated to guidelines.

Expected measurable benefits

The service provision via secure access dashboards and annual headlines reports will be made accessible to personnel with NHS emails, health related charities and approved private health care sector employees. NeoHealthHub intend to generate awareness of the dashboards, annual reports and the potential to generate retrospective study publications initially to medicines optimisation personnel or individuals with medicines efficiencies as a core principle of their role. Based upon feedback gathered during direct interviews with this group, it is expected that they will be initial users of the dashboards who will then further share awareness towards individuals who can either seek further contextual understanding of the results or directly impact the prescribing habits in prescribing locations. Thus, generating benefits to the patients within those locations. It is agreed that sharing health systems data with the research community can also provide insights into strategies to improve the effectiveness and efficiency of health services and measuring the impact of new health policies and interventions. This will be a key principle behind the sharing of data.

NeoHealthHub will also generate awareness with health-related charities who will be able to showcase headlines to their members on relevant areas. This will increase awareness of prescribing variances within the relevant areas and help further increase research potential. Sharing the information with relevant approved personnel within the private sector will increase the potential for awareness within the NHS as the key directive of providing information to this sector will be for them to promote the findings to key personnel within the NHS.

For each private sector request for access, NeoHealthHub Limited will undertake an internal assessment to confirm whether the commercial benefit accruing to the commercial organisation is proportionate to the benefit to health and social care. NeoHealthHub will also seek external review by a current member of the NHS who holds a relevant position (suggested to be a position within medicines optimisation) to ascertain the relevance of the project and the balance of benefit to the health and social care sector, patients and the commercial benefit to the private sector. If it is concluded that this is not the case, the project will either be progressed or rejected in its entirety.

To date 5 members of the NHS have been involved in the initial interviews to scope NeoHealthHub's offerings prior to the initial application and all projects to date have been within these areas that had been agreed would be beneficial to the NHS or have been requested directly from the NHS. The intention for this process is that NeoHealthHub will discuss a prospective analytical output with the NHS member who will determine if it aligns to an NHS priority for understanding. This will enable NeoHealthHub to understand the potential benefit of a given project.

How does the dissemination benefit the provision of health care or adult social care or the promotion of health?

The services provided to clients are expected to identify improvement opportunities which healthcare provider clients may then exploit by making improvements to services, systems, processes, resources or infrastructure in order to improve planning, patient safety and medicines efficiencies. It is also expected that patient safety and medicines effectiveness compliant behaviours would be observed, learnt from and purposefully maintained.

The use of the data could:

• Advance the understanding of prescribing behaviours that may indicate a reduction in patient safety and how these compare across different geographies

• Inform planning health services and programmes, for example to improve equity of access to preferred treatment pathways.

• Advance the contextual understanding of NHS national priorities to increase patient safety and effectiveness of prescribing.

• Lead to the identification or improvement of treatments to improve health and care outcomes or experience.

• Provide a mechanism for checking the quality of care regarding patient safety and effectiveness of prescribing. This could include identifying areas of good practice to learn from, or areas of poorer practice which need to be addressed or prevented from occurring.

• Help the system on insight generation bespoke to NHS or Charity patient safety or medicine effectiveness requests where they do not have sufficient capacity.

• Advance understanding of the need for, or effectiveness of, preventative health and care measures for particular populations or conditions

• Enabling NHS Medicines Optimisation teams to measure, compare and benchmark key quality indicator trends focusing on risk adjusted measures of admissions, readmissions and length of stay in hospital in the context of primary care prescribing.

• Providing evidence to instigate clinical audit and investigations related to quality of care, such as highlighting potential poor clinical coding or quality/efficiency concerns.

• Enabling NHS Medicines Optimisation teams to use performance information to identify, quantify and act on opportunities to improve efficiency of health services.

• Understanding areas of best practice and facilitate interactions with other localities who are not performing as well to support quality and efficiency improvement.

• Helping the NHS by providing independent and authoritative analysis of the variations that exist in prescribing and hospital outcomes in a way that is meaningful for them and that is understandable.

NeoHealthHub Limited will commit to reviewing all non-patient level data publications from NHS England for all analysis undertaken to best use all freely accessible data alongside the data being applied for. This will help to provide further context to the headlines of the data being applied for.

A key aspect of the interviews conducted was to ask members of the NHS perceived benefits to patients, NHS, and the private sector. Below is a summary from these interviews (grouped by therapy areas):

ASTHMA AND COPD (RESPIRATORY)

1. SABA Overuse Combined with ICS underuse – Patient Prescribing Profiling.

Patients being over or under treated are contributors to medicines waste and treatment inefficiencies. The clinical outcomes of these patients have been shown to be worse than well controlled patients which in turn results in additional admissions to hospital. Having simple access to this information will enable actions to be directed in the most requiring areas. It was suggested during the interviews that understanding what the average make up of those patients is and whether they are under or overusing other respiratory medication will enable a plan of potential action to be formalised. With the analysis of historical success section, the user will be able to see whether the processes they have put in place post changes to patient treatment have been successful. This will enable them to review whether the cost and time investment into projects to achieve these targets was justified.

Patients who receive a review of their therapy based upon the change of practice by the Health & Social Care System would benefit from the prospect of reduced risk of exacerbations, admissions and even death.

2. Triple Therapy Treatment.

Access to this information will enable different levels of the NHS to inform and justify projects of review. These reviews hope to result in better patient adherence and persistence and ultimately increase patient care and outcomes. Outcomes may result in lower levels of escalation of care. Reviews of historical changes will also enable refinement of approaches if unsuccessful or reinforcement of these projects.

Patients who receive a review would reduce the number of inhalers they are managing and look forward to the potential of increased adherence and persistence of their treatment. They would then subsequently benefit from the increased clinical outcomes from this result.

3. Inhaler Therapy Review Analysis.

Analysis of persistence post therapy reviews hopes to enable NHS areas to be better informed as to which reviews have the best persistence. They will be able to review their approaches to other areas regarding the prescribing elements of these reviews. They will also be able to isolate stand out success surgeries, PCNs, Sub ICBs and ICBs where the information regarding the logistical aspect of these reviews might be sharable so these also can be integrated into future projects.

Patients are likely to benefit from the improved approaches from the Health & Social Care System. Patients would have therapy reviews that are better informed and would follow case studies of successful reviews undertaken in the past. This would reduce the potential of patients going through reviews that have a lower chance of a low persistence rate.

The private sector could benefit from being able to understand persistence rates which would improve supply management through demand forecasting.

4. Fulfilment of Generic Inhaler Prescriptions.

Analysis of the number of existing and new patients receiving spacers would enable health care professionals to act upon this understanding and promote their increased or sustained usage in line with their local guidance.

Patients would benefit from the improved approaches from the Health & Social Care System. Patients who haven’t had access to a spacer historically may gain this access if the local care system changes policy or promotes it more in certain areas that are not compliant to the guidance.

DIABETES ANALYSIS

1. Diabetes Prescribing Patient Profiles

Each NHS locality will be able to understand what the predominant treatment pathway is for diabetes medication and how this has changed over time. Comparison to other localities will also enable a review of their own outputs.

Variation of prescribing across England is something that is consistently reviewed and has been shown historically to promote different health outcomes because of this. Patients that are being treated for Diabetes in one area could be treated differently to another. If a certain area is not following optimal prescribing guidance and changes in guidance are implemented and enforced because of a heightened awareness, then patients will benefit from receiving optimal prescribing above what they are currently receiving. This in turn would promote better health outcomes.

The private sector would be able to promote access to the dashboard to increase conversations in areas that are not following the latest guidance. If their products are on the guidance this would increase the volume of product being used. But this would be in line with what is being requested from the guidance developers.

2. Out of Stock Events

The health & social care system will benefit from being able to identify patient groups that are being adversely affected by diabetic drug out of stocks and to understand what the actual affects to patients prescribing is occurring at these times. Action plans would then be able to be put in place for the management of these patients.

Patients being affected by out of stocks and going under the radar would benefit from the chosen actions decided upon by the NHS locality based upon the findings of the analysis.

Private sector companies would be able to align their actions to assisting with medication supply when other companies’ products go out of stock. Private sector companies whose own products are going out of stock would be able to be fully aware of the effects that these out of stocks are having on their patients and would hopefully look to plan accordingly.

HEART FAILURE

The health & social care system will benefit from being able to identify patient groups that are being treated in certain ways and review the variance of these between different levels of the NHS and National. Action plans would then be able to be put in place for surgeries or areas that sit outside of what is the best treatment profiles.

Patients who reside in areas that don’t follow what is the most favourable treatment profiles could benefit from having their treatment reviewed or new patients entering treatment could benefit from the new approaches.

Private sector companies would be able to promote access to the dashboards which could in turn increase awareness of a variance in heart failure treatment. If the health and social care sector were to decide to act upon this, it could in turn lead to the increased usage of certain products which may or may not be those of the company promoting the dashboards use but would ultimately be aligned to the local guidelines.

INSOMNIA – CHRONIC INSOMNIA AND INSOMNIA RELATED TO ADHD AND AUTISM SPECTRUM

Each NHS locality will be able to understand what the predominant treatment pathway is when insomnia products are used, they will be able to see what the current prescribing is that falls outside of what is considered to bring optimal safety and how these trends have changed over time. With this insight they would be able to review whether a change in protocol is required or further enforcement required for what they are already promoting.

patients who have been left on Benzodiazepines and Z-drugs for long periods could benefit from having their therapy reviewed. The Long-term use of benzodiazepines or Z-drugs (usually more than 4 weeks) may be associated with:

• Tolerance — a higher dose is required to obtain the initial effect.

• Dependence — the person feels they need the medication to carry out day-to-day activities, and/or withdrawal symptoms occur upon stopping or dose reduction.

• Other effects of long-term use of benzodiazepines include:

• Cognitive effects, anxiety, agoraphobia, emotional blunting, reduced coping skills, and amnesia.

• Reduced social functioning due to effects on memory, reduced ability to remember new people, appointments etc.

• Depression, either for the first time, or aggravation of pre-existing depression with possible precipitation of suicidal tendencies.

• Patients being optimally reviewed could avoid these side effects.

Private sector companies would be able to promote access to the dashboards which could in turn increase awareness of a variance in Benzodiazepines and Z-drugs usage. If the health and social care sector were to decide to act upon this, it could in turn lead to the increased usage of certain products which may or may not be those of the company promoting the dashboards use but would ultimately be aligned to the local guidelines

How will outputs achieve the stated purposes?

Awareness of prescribing inequalities isolated within specific geographies and subsequently the information to act upon these inequalities, could lead to patients receiving optimised care. In response to this new provision of optimal prescribing, the patient outcomes can be expected to improve based upon the clinical decisions for this optimal care being promoted in the first instance.

Medicine overuse is a key measure for the NHS across areas such as respiratory (salbutamol overdependence). The users of the services provided by processing this data will have improved access to information which would allow the systemic review of policies and procedures which may act to improve indicators relating to such overuse. Patients affected by these policies and procedures would in turn benefit from a more controlled provision of these medicines with a potential review of their dispensed medicines.

Certain medicines should be restricted or strictly monitored in use with children or other patient groups. Indicators relating to such medicines and their use in these populations with allow medical professionals to have an awareness and information to act when required. These actions will derive the benefits implied by these restrictions being implemented based on patient safety. The potential benefits may include reduced admissions related to medicines harm and increased effectiveness or reduced complications related to medicines safety issues.

It is hoped that through publication of insights, the findings of this analysis will add to the body of evidence that is considered by the organisations and individual care practitioners charged with making policy decisions for, or within, the NHS or treatment decisions in relation to specific patients.

The NHS will need to take action based on the information provided to them in order to realise the potential improvement opportunities. For example, members of a medicine’s optimisation team may review their region in a dashboard and isolate a prescribing profile that they would like to propose a route of change. This proposal could be sent to a health care professional with the ability to access the data themselves. On review by the HCP they could choose to address the prescribing habits in their practice which would ultimately benefit the patients under their care as they would start on or be reviewed to the perceived optimal treatment.

Working with individuals from the NHS, NeoHealthHub have aligned the proposed outputs to therapy areas that have a significant impact on a large number of patients, therefore increasing the opportunity for benefit due to the sheer scale of those being affected. Due to the variation of prescribing habits within these areas and the number of medicines available, this again increases the magnitude of impact. Based upon statistics taken from relevant charities, there are 5.4 million people currently living with Asmtha in the UK, 1.2 million people living with COPD, 4.8million people currently living with Diabetes in the UK, 0.92 million people with Heart Failure and it is thought that a third of people will suffer from Insomnia at some point in there life. Although the core focus of the teams efforts will be centered on the above therapy areas, NeoHealthHub want to remain flexible to the priorities of the NHS and will therefore reserve a smaller percentage of time to review the potential of outputs within other therapy areas. It is hoped that this approach will enable us to be agile when approached with needs in which is an ever changing treatment environment.

How will it be measured?

A core measurement of benefit will be in reports showing access to the dashboards by NHS personnel, as NeoHealthHub are aligned to the fact that sharing health systems data can provide insights into strategies to improve the effectiveness and efficiency of health services, we can state that the more individuals accessing insights directly requested by the NHS will achieve a benefit.

NeoHealthHub Limited will seek to gain structured feedback from NHS users to understand the level of benefit gained from the utilisation of the services provided, should access to the data be granted. This will be undertaken annually via a web based questionnaire that will contain closed score based questions as well as open free text questions.

All of the above indicators shown within the services provided will be reviewed in annual reports to showcase not only the current headlines but also the changes in practice. Although indirectly, measures showing positive changes in practice within regions accessing the dashboard could be assumed to have received a benefit from the dashboard.

When will it be achieved?

It is accepted that changes in policy and then the implementation of these changes will take time post awareness of the insights being gained. However, it is hoped that the resulting patient benefits will be achieved shortly after annual planning cycles are concluded by the personnel accessing the dashboard insights.

Almost all prescribing indicators or optimisation targets are linked to a patient benefit based upon the proposed intervention. To date NeoHealthHub have been able to review the dynamic trends of interventions aligned to medicines optimisation opportunities, however with the alignment of HES data, the patient benefit will now be measurable and comparable also. These comparisons could be reviewed multiple ways, for example comparing two time periods within the same geography or comparing two/multiple geographies for the same time period. Although there will be multiple other factors to be considered, a direct correlation comparison for different prescribing patterns/achievements against optimisation targets vs relative hospital activity will provide significant insight for the chosen therapy areas. These insights will provide benchmarks from high performing areas and enable local analysts to showcase the potential benefits of engaging in various projects. As the data will be progressively published, progress will also be showcased for geographies to understand the resulting benefits of their medicines optimisation actions.

For example:

1. Optimising lipid management for cardiovascular disease prevention

(referencing National medicines optimisation opportunities 2024/25) :

NHS England’s Cardiovascular disease high impact interventions show that improved lipid management in England can drive better CVD outcomes; after 1 year, every 1 mmol/L reduction in LDL-C reduces a person’s risk of a major vascular event by 25%. If 90% of people with CVD were prescribed a statin and 70% were put onto an optimal dose, this could prevent over 800 strokes and heart attacks in five years. This would save many lives, reduce admissions to hospital, and cut costs to the health and social care system.

Combining the NHSBSA Medicines Dispensed in Primary Care and HES data sets, analysis would make it possible to review the patient percentages being prescribed a statin and the percentage put on an optimal dose. Retrospectively these patients in each cohort could then be reviewed for the volume of hospital activity relevant to this lipid management marker.

2. Reducing Excess Salbutamol prescribing for hospital admission prevention

The NHSBSA medicines dispensed in primary care alone allows for the review of patients receiving excess prescriptions of SABA inhalers. Combining this ongoing analysis will allow for insight generation regarding the published association with poor asthma control and increased risk of hospital admission. This will enable direct comparison between geographies based upon their SABA prescribing indicators as well as the resulting number of asthma based hospital admissions. Publication of historical analysis to show the change overtime of both of these measures will also be made possible so that future actions can be warranted and their patient benefit efficacy assessed and benchmarked.

3. Optimising Prescribing Guidance to reduce hospital referrals

A major element of feedback from our initial interviews with medicines optimisation personnel was about reviewing the utilisation of specific medication prior to referral that could in turn reduce the requirement for a patient to be referred to secondary care. This has a multitude of benefits for the patients as well as reducing the capacity requirements of secondary care services. Combining the NHSBSA medicines dispensed in primary care data with the HES data will allow for the current analysis of such medications to be expanded to analyse the variations in outpatient referrals for patients who have indeed been provided with these medications in contrast to those that have not. This analysis will enable NHS analysts and medicines optimisation personnel to review areas with such product use to understand the potential benefits of adopting similar guidance to other areas and to understand what potential benefits could be achieved for the patients as well as the service providers.

Benefits reported so far

1. Performance of analyses designed from feedback from NHS individuals that have been presented in dashboards and made freely accessible to the broader NHS, with significant uptake from Medicines Optimisation and Prescribing Analysts.

Respiratory disease is a major burden within NHS primary care and there are a vast number of available treatments.

Medicines Optimisation individuals are tasked with providing guidance on the usage of inhalers within primary care and due to the scale of usage and the variety of that usage, including treatment step up, step down and combination therapies, it is a very confusing therapy area to analyse.

The dashboards are now being accessed by individuals representing over 50% of the ICBs within NHS England since the commencement of this agreement. These dashboards have provided them with never before seen information relevant to their ICB. Each section of the respiratory dashboard is aligned to a specific question that has been directly asked of us from one of these individuals.

Example of use: Salbutamol overuse has been a national target for many years now and is tracked in an NHS internal dashboard on a monthly basis, showing a simple measure of the percentage of patients overusing Salbutamol. The team’s analysis has expanded this understanding by showcasing the number of patients with recurring overuse, the number of first-time over users, and the number of patients being brought back under control. This allows the dashboard reviewer to understand whether the actions currently being undertaken are treating the symptoms or curing the problem itself! Direct feedback from a user stated “it is clear that we are reviewing the overusers and bringing them under control, but due to the scale or new patients becoming overusers, the underlying prescribing habits of those involved clearly hasn’t been changed. This will now need to become a joint focus for us.“

The dashboards will enable medicines optimisation leads across NHS England to understand their performance on a range of different prescribing based measures and benchmark themselves against other ICBs. This is achieved with no pay wall or concern for directing internal resource away from other projects. Often ICBs do not have the resource to undertake these analyses themselves and will also benefit from understanding what is being requested by other ICBs.

To date NeoHealthHub have created a dashboard for Respiratory Disease, Chronic Insomnia and are currently in the final design process for Diabetes treatment and Obesity Treatment dashboards. These are being built considering the feedback received from NHS Medicines Optimisation users and relevant experts in the area.

This work has enabled medicines optimisation leads to understand where they need to focus attention for therapeutic strategies for asthma and COPD, as well as planning for current and future treatments for patients.

2. Performance of a number of analyses that have enabled the further bespoke expansion of the dashboards to deliver targeted information related to bespoke requests from the NHS in real time.

The team are committed to maintaining the relevance of the dashboards and advancing this relevance based upon our feedback network.

A national focus within Respiratory therapy has been around triple therapy patients. This is likely to be the case as these patients are in requirement of the most intense therapy and are often of an older age.

Single inhalers containing all three molecules have recently been introduced for prescription in England and the movement of patients from multiple inhaler triple therapy to single inhaler triple therapy has been a project that a number of ICBs have embarked upon. A Lead Respiratory Specialist Pharmacist and NICE Medicines and Prescribing Associate emailed our help desk to request a specific enhancement to the dashboard to enable them to review this scenario over time. Due to the complexity and therefore potential resource burden such an analysis could create, they were unable to request this analysis internally. NeoHealthHub were able to align to the individuals request and develop a specific dashboard extension that would showcase the dynamic change of multiple inhaler triple therapy over time. Direct feedback from a user stated “prior to this analysis I was unsure of the scale of the number of patients still using multiple inhalers where they could be offered the option of using one. This move could help to increase their medicines compliance and make sure they are consistently receiving all three medicines that their clinician believes them to require. We can now align our resource to the scale of this project more effectively and also review our levels of success”.

This service provides members of the NHS with the ability to request highly bespoke data and dashboard developments in a timescale aligned to their needs.

Medicines Optimisation teams have been able to utilise these bespoke dashboard advancements for internal meetings to reinforce their project presentations saving them time and providing them with a robust planning basis.

3. The team have allocated 240 hours of analytical resource per year to be freely available to the NHS for bespoke data requests that are not covered by the dashboard currently or may not be best suited for a dashboard presentation.

The team have proactively promoted the availability of free to access dashboards for the NHS as well as having a designated resource to assist them in their analytical requirements.

An ICB prescribing analyst was reviewing volumes of a specific inhaler that the ICB had recently deprioritised for a medicines review project which would potentially promote the movement from it to a more cost effective inhaler containing the same molecule in a similar device. The analyst was currently reviewing GP prescribing data at a surgery level. Although the volumes were providing an overview of what was occurring, the analyst was unable to understand what was happening to patients post them moving to an alternative inhaler. Due to the complexity of this request and the time scale that it was required within, it was determined that this could not be provided by the NHS analysts available to them and they were unable work out how to answer it themselves. A request came into our help desk to review the project. NeoHealthHub produced a surgery level analysis to review all patients that had moved from an originator brand inhaler to a branded generic of the same molecule and device type in the last 5 years. These patients were then reviewed to understand whether they persisted on the new inhaler, moved back to the originator brand or moved to a different treatment altogether. This analysis was the repeated for the present day to understand what all of these patients were being treated with now. Surgery information was provided to the requester but it was also recreated at an ICB level for inclusion into the dashboard in the next update.

Direct feedback to us from this requester stated “This analysis has enabled me to understand the scale of the project I am reviewing as well as those that have been undertaken before. We don’t want to change patients medication for the sake of it and this analysis has helped us understand that the majority of the times these changes are well tolerated in terms of the patients persisting on the new therapy. However there are times and in specific Medical Centres, that these reviews have not been well tolerated and we now need to find out why so that we can learn from what has gone wrong. We now know where these surgeries are that had these issues and we obviously now know that these issues even existed”.

A long Term Conditions pharmacist was working on a product specifically reviewing juvenile Asthma and the treatment patterns being utilised. They posed a question for us to combine the Salbutamol overuse measure with the patient age profiling measure to showcase the number of children overusing Salbutamol.

Direct feedback from this requester stated “Although the analysis is simple, this is the only dataset known to me that could have answered it with such detail. This analysis has enabled the understanding that although a problem exists, the volume is in decline for my area and therefore my focus can be applied elsewhere”.

NeoHealthHub Limited engagement with the ICBs has led to increasing number of users requesting access within the individual ICBs, which in turn has led to requests for different outputs, for example, surgery level output of the respiratory dashboard. Provision of the dashboards have also been requested by ICBs to explore providing an overview of all of their work with the medicines dispensed in primary care data set as an introduction to what can be done with the data.

Datasets on the latest version

Legal basis for provision: Health and Social Care Act 2012 – s261(2)(a)

Datasets approved under DARS-NIC-692602-Q6P4F-v4.4
Dataset	Type of data	Sensitivity	Frequency	Confidential data
Emergency Care Data Set (ECDS)	Anonymised - ICO Code Compliant	Non-Sensitive	System Access	Does not include the flow of confidential data
Hospital Episode Statistics Admitted Patient Care (HES APC)	Anonymised - ICO Code Compliant	Non-Sensitive	System Access	Does not include the flow of confidential data
Hospital Episode Statistics Outpatients (HES OP)	Anonymised - ICO Code Compliant	Non-Sensitive	System Access	Does not include the flow of confidential data
Medicines dispensed in Primary Care (NHSBSA data)	Anonymised - ICO Code Compliant	Non-Sensitive	System Access	Does not include the flow of confidential data

Files released

Files released counts only files released externally by DARS. Access granted in NHS England's own systems, such as its Secure Data Environment, is not included.

No files recorded as released under this agreement.

Version history

The register lists each renewal of this agreement as a separate row. This site has 5 versions.

DARS-NIC-692602-Q6P4F-v4.4 14 February 2025 to 13 February 2026

Title: Data modelling and analytics - Primary Care Prescribing and Primary Care Prescribing Impact on Secondary Care activity
Commercial: Yes
Sublicensing: No
Datasets: 4
Files released: 0

Datasets: Emergency Care Data Set (ECDS); Hospital Episode Statistics Admitted Patient Care (HES APC); Hospital Episode Statistics Outpatients (HES OP); Medicines dispensed in Primary Care (NHSBSA data)

What changed from DARS-NIC-692602-Q6P4F-v3.2

Text removed is ~~struck through~~; text added is underlined. Unchanged paragraphs are summarised rather than repeated.

Fields changed from DARS-NIC-692602-Q6P4F-v3.2
Field	Was	Became
Title	~~Data modelling and analytics~~	Data modelling and analytics - Primary Care Prescribing and Primary Care Prescribing Impact on Secondary Care activity
Start date	~~2024-11-22~~	2025-02-14
End date	~~2025-11-21~~	2026-02-13

Datasets: + Emergency Care Data Set (ECDS); + Hospital Episode Statistics Admitted Patient Care (HES APC); + Hospital Episode Statistics Outpatients (HES OP)

Objective for processing

Neo Health Hub Limited requires access to NHS England ~~Data~~ for the purpose of providing the following services to clients in the health ~~sector.~~ sector: • Online tools and services – management information, analysis and clinical benchmarking, and consultancy; • Bespoke analytics – customised projects to meet individual needs; • Research for publication – thought leadership in the field of healthcare data analytics, with the aim of improving the planning, delivery and outcome of health and social care. We believe that these offerings utilising both the Patient Level Prescribing Data and linked HES will provide a unique solution for the NHS and non NHS organisations. NHS clients access analysis of the data to: • Review prescribing trends and the association to secondary care performance measures. • Track and trend performance, identify areas for efficiency savings and understand and influence demand and patient flow throughout the health and care system. • Investigate risk-adjusted quality, patient safety and clinical outcomes data, benchmark against other healthcare organisations and to help improve the quality of patient care and identify areas for improvement. All of the above will be in relation to the Primary Care Prescribing cohorts developed from the linked medicines dispensed in primary care data. [2 paragraphs unchanged] • Integrated Care ~~Systems/ Boards (ICSs/ICBs)~~ Systems ~~• Sustainability and Transformation Partnerships (STPs)~~ • Integrated Care Boards ~~• Primacy Care Teams (including GPs / Nurses)~~ • Commissioning Support Units ~~• Pharmaceutical companies~~ • Department of Health and Social Care ~~• Medical Device companies~~ • NHS England • UK Health Security Agency and Office for Health Improvement and Disparities • National Institute for Health and Care Excellence Neo Health Hub Limited will also work with: • Non-NHS organisations providing services to benefit the NHS - these are only supplied with aggregate, small-number suppressed analyses in line with the HES analysis guide. • Non-NHS organisations to benefit public health and social care - these are only supplied with aggregate, small-number suppressed analyses where benefits can be identified for the health and social care system. Algorithms or coefficients that have been derived through research on HES data may be provided directly to a customer for implementation on their own local data. Data provided in all outputs to non-NHS organisations will be at an aggregate level and small number suppression will be implemented in line with HES analysis guidelines. [1 paragraph unchanged] • Variations in health outcomes in the context of primary care prescribing • Health inequalities and needs analysis in the context of primary care prescribing • Predictions • Performance data and changes in clinical practice and prescribing • Efficiency monitoring [1 paragraph unchanged] ~~• Care pathway analysis~~ • Activity monitoring ~~• Hospital feedback services~~ • National target performance ~~• Health economics and outcomes research studies~~ • Practice performance monitoring ~~• Clinical trial analysis~~ • Capacity and utilisation management • Patient segmentation analysis • Overall data quality [1 paragraph unchanged] Neo Health Hub Limited utilizes expert pharmaceutical domain expertise to meet data modelling & analytic needs throughout the ~~healthcare sector, as well as software~~ healthpital feedback services development to produce tools and reports used by health and social care. Data from NHS England is required to achieve the following fundamental aims: [42 paragraphs unchanged] • Medicines dispensed in Primary Care (NHSBSA data) – necessary to provide information [20 words unchanged] the relevant indicators required to build resources aimed at supporting medicine optimisation. Linked Medicines dispensed in Primary Care (NHSBSA data) – the core aspect of this application is to provide insights in the form of hospital activity relating to prescribing variations in primary care. The Medicines dispensed in primary care data will bring all of the other data sets together to enable to creation of patient prescribing profiles that will then be assessed in relation to hospital activity. - Hospital Episode Statistics Admitted Patient Care – due to the nature of the analysis combining primary care prescribing data and HES data, the predominant focus will be on chronic care. This is a significant proportion of the patients that are admitted into hospital and will provide significant context to the prescribing patterns in primary care and the impact it has on patients being admitted into hospital. Emergency Care Dataset– many chronic illnesses result in acute ailments, for example diabetes and stroke. Understanding the accident and emergency attendances and the nature of these attendances will give further insightful context to the other data within this application Outpatients- patients with chronic illness will have consistent follow ups and referrals into hospital. The Outpatient HES publication will provide information that will showcase the overall volume of these attendances to be able to provide comparable context geographical and between prescribing profiles. [2 paragraphs unchanged] • Limited to 5 6 full years of data at any one time [8 paragraphs unchanged]

Processing activities

[1 paragraph unchanged] NHS England data will provide the relevant records from the Medicines dispensed in Primary Care (NHSBSA ~~data)~~ data), records from the Hospital Episode Statistics Admitted Patient Care, Emergency Care Dataset, and Outpatients datasets to NeoHealthHub Limited via the NHS England Secure Data Environment (SDE). [25 words unchanged] the possession of the recipient. There are no further flows of data. [30 paragraphs unchanged] · Prescribing trend analysis: Present users with views of prescribing pathways for [12 words unchanged] the causes of variant in patient prescribing pathways and subsequent impact on ~~polypharmacy~~ polypharmacy, costs and ~~costs.~~ hospital activity. [1 paragraph unchanged]

Expected output

[5 paragraphs unchanged] The outputs will be communicated to relevant recipients through the NeoHealthHub Limited's [16 words unchanged] a secure online portal containing the dashboards produced by this data processing. With the first dashboard (Respiratory phase 1) now being live, it is expected that further dashboards will continue to be released every 2 months. The respiratory annual report is now going through final review and Diabetes annual report will also follow. Production of any retrospective studies will be within the 2 year agreement proposed but publication timescales are unknown. In June 2024 NeoHealthHub Limited launched its first Free to access for the NHS online dashboard focused on providing patient level analysis for prescribing patterns in the respiratory therapy area. In July 2024 NeaHealthHub Limited launched its second free to access for the NHS online dashboard focused on providing patient level analysis for prescribing patterns for Insomnia. 52 NHS personnel have now registered for access to these dashboards. NeoHealthHub Limited have committed to maintaining the alignment of these dashboards to NHS requirements by collating monthly feedback submissions for requested enhancements and evolutions. NeoHealthHub Limited have committed 240 hours per annum for bespoke NHS analytics across both data sharing agreements. Bespoke NHS requirements will be proactively sought out and provided on a first come first served basis. However, if multiple requests are received simultaneously, NeoHealthHub Limited will determine the order of delivery based upon the internally perceived level of benefit from the analysis. NeoHealthHub Limited reserve the right to provide more hours than committed for additional projects. To date NeoHealthHub Limited have been approached by: Kings College London and Menopause UK to utilise the data in a publication titled 'Understanding Cardiovascular Risk in High-Risk Women: exploring new opportunities to improve outcomes with menopause hormone therapy'. This project is ongoing and will conclude June 2025. Research will contribute to improving health equity by: 1. Highlighting inequities in menopause hormone therapy (MHT) prescribing 2. Exploring reasons for differences in MHT prescribing for underserved women Linking the medicines dispensed in primary care data product to records from the Hospital Episode Statistics Admitted Patient Care, Emergency Care Dataset, and Outpatients datasets will enable all of our current services to be expanded to showcase more than just prescribing change outcomes and significantly increase the understanding of association, correlation and potential causation of outcomes in patients predominantly treated in primary care. An example proposal is to review the significant analysis already undertaken for SABA inhaler overuse and directly align the Asthma admissions data to those patients with consistent SABA inhaler overuse in comparison to those treated to guidelines.

Expected measurable benefits

[14 paragraphs unchanged] • Enabling NHS Medicines Optimisation teams to measure, compare and benchmark key quality indicator trends focusing on risk adjusted measures of admissions, readmissions and length of stay in hospital in the context of primary care prescribing. • Providing evidence to instigate clinical audit and investigations related to quality of care, such as highlighting potential poor clinical coding or quality/efficiency concerns. • Enabling NHS Medicines Optimisation teams to use performance information to identify, quantify and act on opportunities to improve efficiency of health services. • Understanding areas of best practice and facilitate interactions with other localities who are not performing as well to support quality and efficiency improvement. • Helping the NHS by providing independent and authoritative analysis of the variations that exist in prescribing and hospital outcomes in a way that is meaningful for them and that is understandable. [53 paragraphs unchanged] Almost all prescribing indicators or optimisation targets are linked to a patient benefit based upon the proposed intervention. To date NeoHealthHub have been able to review the dynamic trends of interventions aligned to medicines optimisation opportunities, however with the alignment of HES data, the patient benefit will now be measurable and comparable also. These comparisons could be reviewed multiple ways, for example comparing two time periods within the same geography or comparing two/multiple geographies for the same time period. Although there will be multiple other factors to be considered, a direct correlation comparison for different prescribing patterns/achievements against optimisation targets vs relative hospital activity will provide significant insight for the chosen therapy areas. These insights will provide benchmarks from high performing areas and enable local analysts to showcase the potential benefits of engaging in various projects. As the data will be progressively published, progress will also be showcased for geographies to understand the resulting benefits of their medicines optimisation actions. For example: 1. Optimising lipid management for cardiovascular disease prevention (referencing National medicines optimisation opportunities 2024/25) : NHS England’s Cardiovascular disease high impact interventions show that improved lipid management in England can drive better CVD outcomes; after 1 year, every 1 mmol/L reduction in LDL-C reduces a person’s risk of a major vascular event by 25%. If 90% of people with CVD were prescribed a statin and 70% were put onto an optimal dose, this could prevent over 800 strokes and heart attacks in five years. This would save many lives, reduce admissions to hospital, and cut costs to the health and social care system. Combining the NHSBSA Medicines Dispensed in Primary Care and HES data sets, analysis would make it possible to review the patient percentages being prescribed a statin and the percentage put on an optimal dose. Retrospectively these patients in each cohort could then be reviewed for the volume of hospital activity relevant to this lipid management marker. 2. Reducing Excess Salbutamol prescribing for hospital admission prevention The NHSBSA medicines dispensed in primary care alone allows for the review of patients receiving excess prescriptions of SABA inhalers. Combining this ongoing analysis will allow for insight generation regarding the published association with poor asthma control and increased risk of hospital admission. This will enable direct comparison between geographies based upon their SABA prescribing indicators as well as the resulting number of asthma based hospital admissions. Publication of historical analysis to show the change overtime of both of these measures will also be made possible so that future actions can be warranted and their patient benefit efficacy assessed and benchmarked. 3. Optimising Prescribing Guidance to reduce hospital referrals A major element of feedback from our initial interviews with medicines optimisation personnel was about reviewing the utilisation of specific medication prior to referral that could in turn reduce the requirement for a patient to be referred to secondary care. This has a multitude of benefits for the patients as well as reducing the capacity requirements of secondary care services. Combining the NHSBSA medicines dispensed in primary care data with the HES data will allow for the current analysis of such medications to be expanded to analyse the variations in outpatient referrals for patients who have indeed been provided with these medications in contrast to those that have not. This analysis will enable NHS analysts and medicines optimisation personnel to review areas with such product use to understand the potential benefits of adopting similar guidance to other areas and to understand what potential benefits could be achieved for the patients as well as the service providers.

Unchanged: Benefits reported.

DARS-NIC-692602-Q6P4F-v3.2 22 November 2024 to 21 November 2025

Title: Data modelling and analytics
Commercial: Yes
Sublicensing: No
Datasets: 1
Files released: 0

Datasets: Medicines dispensed in Primary Care (NHSBSA data)

What changed from DARS-NIC-692602-Q6P4F-v2.2

Text removed is ~~struck through~~; text added is underlined. Unchanged paragraphs are summarised rather than repeated.

Fields changed from DARS-NIC-692602-Q6P4F-v2.2
Field	Was	Became
Start date	~~2024-07-24~~	2024-11-22
End date	~~2024-11-25~~	2025-11-21

Objective for processing

Neo Health Hub Limited requires access to NHS England Data for the purpose of providing services to clients in the health sector. The Data will be used to provide services to the following types of clients only: • NHS Trusts • Integrated Care Systems/ Boards (ICSs/ICBs) • Sustainability and Transformation Partnerships (STPs) • Primacy Care Teams (including GPs / Nurses) • Pharmaceutical companies • Medical Device companies The Data will be used to provide the following services only: • Benchmarking • Care pathway analysis • Hospital feedback services • Health economics and outcomes research studies • Clinical trial analysis [43 paragraphs unchanged] The following ~~pseudonymised~~ NHS England ~~data is requested:~~ Data will be accessed: [1 paragraph unchanged] ~~DATA MINIMISATION:~~ The level of the data will be pseudonymised. Data will be limited to the latest available and historic data over a five year period. Access to this fixed data period will be maintained within the SDE throughout the Data Sharing Agreement period. The data will be minimised further for each project of work by focusing on specific medicines within the dataset. Analysis will be minimised within the Secure Data Environment (SDE). The minimisation per use will be reviewed and approved by the Data Controller’s Managing Director & Director of Information Technology. The data will be minimised as follows: ~~CONTROLLERSHIP~~ • Limited to 5 full years of data at any one time NeoHealthHub Limited is the controller as the organisation responsible for determining the purpose and means of the processing. For each project undertaken, NeoHealthHub will seek external review by a current member of the NHS (NeoHealthHub Limited have several NHS colleagues working with the organisation on a temporary contract basis. NHH Ltd consult this member when there is a new project and whether the project aligns with a wider piece of work . The aim is to make sure there is a legitimate purpose and benefit to access this tool for the NHS) who holds a relevant position (suggested to be a position within medicines optimisation) to ascertain the relevance of the project and the balance of benefit to the health and social care sector, patients and the commercial benefit to the private sector. Any private sector procuring access to the outputs will need to agree that the outputs will not be used for promoting or marketing of their products. • Limited to data fields which are necessary to deliver products and services that benefit health and care in the UK ~~NeoHealthHub Limited is self-funding this work through the company's main core income stream which is subscription fees paid by pharmaceutical and healthcare companies.~~ Neo Health Hub Limited is the controller as the organisation responsible for ensuring that the data will only be processed for the purposes described above. ~~LAWFUL BASIS~~ [5 paragraphs unchanged] The funding is provided by NeoHealthHub. The funding is specifically for the project described. There is no set end date for the funding at this stage.

Processing activities

[10 paragraphs unchanged] The data will be stored on servers at NHS England via the SDE. The data will be accessed by authorised personnel via remote access to the Secure Data Environment. Personnel are prohibited from downloading or copying data to local devices. The data will not leave England at any time. The Data will not be transferred to any other location. Access is restricted to employees or agents of NeoHealthHub Limited who have authorisation from the Managing Director. All personnel accessing the data have been appropriately trained in data protection and confidentiality. The Data will be stored on servers at NHS England via the SDE. The data will not be linked with any other data. There will be no requirement and no attempt to reidentify individuals when using the data. Analysts from the NeoHealthHub Limited will process the data for the purposes described above. The Data will be accessed by authorised personnel via remote access. The Controller(s) must confirm and provide evidence upon audit by NHS England that access via any remote device complies with the data security obligations within this DSA and the Data Sharing Framework Contract. For remote access: - Remote access will only be from secure locations situated within the territory of use (as further restricted elsewhere within the DSA if so done) stated within this DSA; - Access controls granting users the minimum level of access required are in place; - Remote access is only via secure connections (e.g., VPNs or secure protocols) to protect data; - Multifactor authentication (MFA) is required for remote access; - Device security, including up-to-date software and operating systems, antivirus software, and enabled firewalls are utilised for the remote access; - All remote access is undertaken within the scope of the organisation’s DSPT (or other security arrangements as per this DSA) and complies with the organisation’s remote access policy. The above applies in addition to any condition set out elsewhere within the DSA (e.g. who may carry out processing, and for what purpose). Remote processing will be from secure locations within: England. The data will not leave: England at any time. Access is restricted to employees of NeoHealthHub Limited who have authorisation from the Managing Director. All personnel accessing the data have been appropriately trained in data protection and confidentiality. The data will not be linked with any other data. There will be no requirement and no attempt to reidentify individuals when using the data. Analysts from the NeoHealthHub Limited will process the data for the purposes described above. [6 paragraphs unchanged]

Expected output

[5 paragraphs unchanged] The outputs will be communicated to relevant recipients through the NeoHealthHub Limited's [40 words unchanged] expected that further dashboards will continue to be released every 2 months. ~~Our~~ The respiratory annual report is now going through ~~finalreview~~ final review and Diabetes annual report will also ~~follow in the next 2 months.~~ follow. Production of any retrospective studies will be within the 2 year agreement proposed but publication timescales are unknown.

Expected measurable benefits

The service provision via secure access dashboards and annual headlines reports will [13 words unchanged] private health care sector employees. NeoHealthHub intend to generate awareness of the ~~dashboards ,annual~~ dashboards, annual reports and the potential to generate ~~restrospective~~ retrospective study publications initially to medicines optimisation personnel or individuals with medicines efficiencies [97 words unchanged] new health policies and interventions. This will be a key principle behind ~~our~~ the sharing of data. [1 paragraph unchanged] For each private sector request for access, NeoHealthHub Limited will undertake an [65 words unchanged] social care sector, patients and the commercial benefit to the private sector. If it is concluded that this is not the case, the project will either be progressed or rejected in its entirety. ~~If it is concluded that this is not the case, the project will either be progressed or rejected in its entirety.~~ To date 5 members of the NHS have been involved in the initial interviews to scope NeoHealthHub's offerings prior to the initial application and all projects to date have been within these areas that had been agreed would be beneficial to the NHS or have been requested directly from the NHS. The intention for this process is that NeoHealthHub will discuss a prospective analytical output with the NHS member who will determine if it aligns to an NHS priority for understanding. This will enable NeoHealthHub to understand the potential benefit of a given project. [56 paragraphs unchanged] Working with individuals from the NHS, NeoHealthHub have aligned the proposed outputs [104 words unchanged] Insomnia at some point in there life. Although the core focus of ~~our~~ the teams efforts will be centered on the above therapy areas, NeoHealthHub want to [39 words unchanged] when approached with needs in which is an ever changing treatment environment. [1 paragraph unchanged] A core measurement of benefit will be in reports showing access to the dashboards by NHS personnel, as we NeoHealthHub are aligned to the fact that sharing health systems data can provide [18 words unchanged] individuals accessing insights directly requested by the NHS will achieve a benefit. [4 paragraphs unchanged]

Benefits reported

Phase 1 of our Respiratory Dashboard has been concluded and users are able to view interactive maps, dashboards and tables showing ICB and Sub ICB organisations. Registration and access to the site is available without charge to anyone with an NHS email address. Medicines Optimisation personnel will be able to make more informed decisions on Respiratory medicines optimisation project prioritisation. Our Insomnia Dashboard will be concluded by the end of July 2024 which will be available in a the same way. 1. Performance of analyses designed from feedback from NHS individuals that have been presented in dashboards and made freely accessible to the broader NHS, with significant uptake from Medicines Optimisation and Prescribing Analysts. We currently have just under 30 NHS users with 12 ICBs being represented along with 5 different PCNs. 3 requests have been made for specific further insights within the dashboard, 1 has been concluded and deployed (SABA Overuse by age bracket) and 2 others are currently in development. Respiratory disease is a major burden within NHS primary care and there are a vast number of available treatments. ~~An NHS educational body has also approached us to work in collaboration with them to deploy specific dashboard modules relating to areas of education for respiratory.~~ Medicines Optimisation individuals are tasked with providing guidance on the usage of inhalers within primary care and due to the scale of usage and the variety of that usage, including treatment step up, step down and combination therapies, it is a very confusing therapy area to analyse. Successful application for a grant alongside Kings College London and Menopause UK to utilise the data in a publication titled 'Understanding Cardiovascular Risk in High-Risk Women: exploring new opportunities to improve outcomes with menopause hormone therapy'. This project is ongoing and will conclude June 2025. Research will contribute to improving health equity by: The dashboards are now being accessed by individuals representing over 50% of the ICBs within NHS England since the commencement of this agreement. These dashboards have provided them with never before seen information relevant to their ICB. Each section of the respiratory dashboard is aligned to a specific question that has been directly asked of us from one of these individuals. ~~1. Highlighting inequities in menopause hormone therapy (MHT) prescribing~~ Example of use: Salbutamol overuse has been a national target for many years now and is tracked in an NHS internal dashboard on a monthly basis, showing a simple measure of the percentage of patients overusing Salbutamol. The team’s analysis has expanded this understanding by showcasing the number of patients with recurring overuse, the number of first-time over users, and the number of patients being brought back under control. This allows the dashboard reviewer to understand whether the actions currently being undertaken are treating the symptoms or curing the problem itself! Direct feedback from a user stated “it is clear that we are reviewing the overusers and bringing them under control, but due to the scale or new patients becoming overusers, the underlying prescribing habits of those involved clearly hasn’t been changed. This will now need to become a joint focus for us.“ ~~2. Exploring reasons for differences in MHT prescribing for underserved women~~ The dashboards will enable medicines optimisation leads across NHS England to understand their performance on a range of different prescribing based measures and benchmark themselves against other ICBs. This is achieved with no pay wall or concern for directing internal resource away from other projects. Often ICBs do not have the resource to undertake these analyses themselves and will also benefit from understanding what is being requested by other ICBs. Final draft of our Respiratory Annual Review is now in final review and will be proactively made available free of charge to NHS medicines optimisation teams primarily and anyone with an NHS email address requesting access. To date NeoHealthHub have created a dashboard for Respiratory Disease, Chronic Insomnia and are currently in the final design process for Diabetes treatment and Obesity Treatment dashboards. These are being built considering the feedback received from NHS Medicines Optimisation users and relevant experts in the area. This work has enabled medicines optimisation leads to understand where they need to focus attention for therapeutic strategies for asthma and COPD, as well as planning for current and future treatments for patients. 2. Performance of a number of analyses that have enabled the further bespoke expansion of the dashboards to deliver targeted information related to bespoke requests from the NHS in real time. The team are committed to maintaining the relevance of the dashboards and advancing this relevance based upon our feedback network. A national focus within Respiratory therapy has been around triple therapy patients. This is likely to be the case as these patients are in requirement of the most intense therapy and are often of an older age. Single inhalers containing all three molecules have recently been introduced for prescription in England and the movement of patients from multiple inhaler triple therapy to single inhaler triple therapy has been a project that a number of ICBs have embarked upon. A Lead Respiratory Specialist Pharmacist and NICE Medicines and Prescribing Associate emailed our help desk to request a specific enhancement to the dashboard to enable them to review this scenario over time. Due to the complexity and therefore potential resource burden such an analysis could create, they were unable to request this analysis internally. NeoHealthHub were able to align to the individuals request and develop a specific dashboard extension that would showcase the dynamic change of multiple inhaler triple therapy over time. Direct feedback from a user stated “prior to this analysis I was unsure of the scale of the number of patients still using multiple inhalers where they could be offered the option of using one. This move could help to increase their medicines compliance and make sure they are consistently receiving all three medicines that their clinician believes them to require. We can now align our resource to the scale of this project more effectively and also review our levels of success”. This service provides members of the NHS with the ability to request highly bespoke data and dashboard developments in a timescale aligned to their needs. Medicines Optimisation teams have been able to utilise these bespoke dashboard advancements for internal meetings to reinforce their project presentations saving them time and providing them with a robust planning basis. 3. The team have allocated 240 hours of analytical resource per year to be freely available to the NHS for bespoke data requests that are not covered by the dashboard currently or may not be best suited for a dashboard presentation. The team have proactively promoted the availability of free to access dashboards for the NHS as well as having a designated resource to assist them in their analytical requirements. An ICB prescribing analyst was reviewing volumes of a specific inhaler that the ICB had recently deprioritised for a medicines review project which would potentially promote the movement from it to a more cost effective inhaler containing the same molecule in a similar device. The analyst was currently reviewing GP prescribing data at a surgery level. Although the volumes were providing an overview of what was occurring, the analyst was unable to understand what was happening to patients post them moving to an alternative inhaler. Due to the complexity of this request and the time scale that it was required within, it was determined that this could not be provided by the NHS analysts available to them and they were unable work out how to answer it themselves. A request came into our help desk to review the project. NeoHealthHub produced a surgery level analysis to review all patients that had moved from an originator brand inhaler to a branded generic of the same molecule and device type in the last 5 years. These patients were then reviewed to understand whether they persisted on the new inhaler, moved back to the originator brand or moved to a different treatment altogether. This analysis was the repeated for the present day to understand what all of these patients were being treated with now. Surgery information was provided to the requester but it was also recreated at an ICB level for inclusion into the dashboard in the next update. Direct feedback to us from this requester stated “This analysis has enabled me to understand the scale of the project I am reviewing as well as those that have been undertaken before. We don’t want to change patients medication for the sake of it and this analysis has helped us understand that the majority of the times these changes are well tolerated in terms of the patients persisting on the new therapy. However there are times and in specific Medical Centres, that these reviews have not been well tolerated and we now need to find out why so that we can learn from what has gone wrong. We now know where these surgeries are that had these issues and we obviously now know that these issues even existed”. A long Term Conditions pharmacist was working on a product specifically reviewing juvenile Asthma and the treatment patterns being utilised. They posed a question for us to combine the Salbutamol overuse measure with the patient age profiling measure to showcase the number of children overusing Salbutamol. Direct feedback from this requester stated “Although the analysis is simple, this is the only dataset known to me that could have answered it with such detail. This analysis has enabled the understanding that although a problem exists, the volume is in decline for my area and therefore my focus can be applied elsewhere”. NeoHealthHub Limited engagement with the ICBs has led to increasing number of users requesting access within the individual ICBs, which in turn has led to requests for different outputs, for example, surgery level output of the respiratory dashboard. Provision of the dashboards have also been requested by ICBs to explore providing an overview of all of their work with the medicines dispensed in primary care data set as an introduction to what can be done with the data.

Objective for processing

Neo Health Hub Limited requires access to NHS England Data for the purpose of providing services to clients in the health sector.

The Data will be used to provide services to the following types of clients only:

• NHS Trusts

• Integrated Care Systems/ Boards (ICSs/ICBs)

• Sustainability and Transformation Partnerships (STPs)

• Primacy Care Teams (including GPs / Nurses)

• Pharmaceutical companies

• Medical Device companies

The Data will be used to provide the following services only:

• Benchmarking

• Care pathway analysis

• Hospital feedback services

• Health economics and outcomes research studies

• Clinical trial analysis

BACKGROUND:

Neo Health Hub Limited utilizes expert pharmaceutical domain expertise to meet data modelling & analytic needs throughout the healthcare sector, as well as software development to produce tools and reports used by health and social care. Data from NHS England is required to achieve the following fundamental aims:

1. Comprehension and quantification of the prescribing trends across NHS England primary Care.

2. Through robust research, to not only add to the body of healthcare knowledge but reveal key prescribing trends and patterns over time in NHS prescribing activity.

3. Application of data to identify key prescribing improvements in terms of the alignment to national benchmarks and consistency of prescribing.

4. Provide solutions to support commissioning, analytical support, and outcomes analytics for NHS organisations, ranging from NHS England to regional teams.

The intention of the processing is to:

· Achieve widespread benefits to healthcare, including changes to patient care, reduced cost burden and uptake and monitoring of current health policies.

· Contribution of the already existing knowledge within the medical community to ignite further research into improving patient care.

• NHS Trusts

• Integrated Care Systems/Boards (ICSs/ICBs)

• Sustainability and Transformation Partnerships (STPs)

• Primacy Care Teams (including GPs / Nurses)

• Pharmaceutical companies

• Medical Device companies

Expected User Type – Private

Expected User Type – NHS

INTERVIEWS

• What therapy areas would be of interest to receive further analysis on ?

• How they would use this information?

• How the information would be used to benefit the health and social care sector?

• How the information would benefit the patients within the health and social care sector?

The interviewees flagged that the best delivery formats for the analysis would be:

• A secure web based dashboard for each therapy area

• An annual report for each therapy area that showcases headlines of the dashboard

NeoHealthHub Limited agreed with the interviewees that the therapy areas with the broadest potential benefit for the analysis would be:

• Asthma and COPD (respiratory)

• Diabetes

• Heart Failure

• Insomnia (with a focus on addictive medicines)

Although the focus will remain on the above areas, NeoHealthHub will remain reactive to NHS priorities with potential analysis in other areas, for example:

HRT therapy, Opioids, Anti Depressants & Obesity.

Unlimited access will be granted to any user from the NHS or a registered healthcare charity free of charge.

The following NHS England Data will be accessed:

• Medicines dispensed in Primary Care (NHSBSA data) – necessary to provide information including what types of medication are being prescribed to patients nationally, as well as their frequency. The data will provide the relevant indicators required to build resources aimed at supporting medicine optimisation.

The level of the data will be pseudonymised.

The data will be minimised as follows:

• Limited to 5 full years of data at any one time

• Limited to data fields which are necessary to deliver products and services that benefit health and care in the UK

Neo Health Hub Limited is the controller as the organisation responsible for ensuring that the data will only be processed for the purposes described above.

The lawful basis for processing personal data under the UK GDPR is:

The lawful basis for processing special category data under the UK GDPR is:

The funding is provided by NeoHealthHub. The funding is specifically for the project described. There is no set end date for the funding at this stage.

Expected output

The expected outputs of the processing will be:

• Monthly updated dashboards accessed by the NHS selected Charities and vetted private sector employees.

• Annual therapy area reports showcasing headlines from the dashboards developed

• Aggregated data tabulation provision in combination to retrospective studies.

The outputs will be communicated to relevant recipients through the NeoHealthHub Limited's portal being developed solely for this purpose. Clients to the service will be provided access to a secure online portal containing the dashboards produced by this data processing. With the first dashboard (Respiratory phase 1) now being live, it is expected that further dashboards will continue to be released every 2 months. The respiratory annual report is now going through final review and Diabetes annual report will also follow. Production of any retrospective studies will be within the 2 year agreement proposed but publication timescales are unknown.

Benefits reported

Respiratory disease is a major burden within NHS primary care and there are a vast number of available treatments.

2. Performance of a number of analyses that have enabled the further bespoke expansion of the dashboards to deliver targeted information related to bespoke requests from the NHS in real time.

The team are committed to maintaining the relevance of the dashboards and advancing this relevance based upon our feedback network.

This service provides members of the NHS with the ability to request highly bespoke data and dashboard developments in a timescale aligned to their needs.

The team have proactively promoted the availability of free to access dashboards for the NHS as well as having a designated resource to assist them in their analytical requirements.

DARS-NIC-692602-Q6P4F-v2.2 24 July 2024 to 25 November 2024

Title: Data modelling and analytics
Commercial: Yes
Sublicensing: No
Datasets: 1
Files released: 0

Datasets: Medicines dispensed in Primary Care (NHSBSA data)

What changed from DARS-NIC-692602-Q6P4F-v1.3

Text removed is ~~struck through~~; text added is underlined. Unchanged paragraphs are summarised rather than repeated.

Fields changed from DARS-NIC-692602-Q6P4F-v1.3
Field	Was	Became
Start date	~~2024-06-27~~	2024-07-24
End date	~~2024-07-25~~	2024-11-25

Benefits reported

Phase 1 of our Respiratory Dashboard has been concluded and users are [46 words unchanged] project prioritisation. Our Insomnia Dashboard will be concluded by the end of ~~June~~ July 2024 which will be available in a the same way. We currently have just under 30 NHS users with 12 ICBs being represented along with 5 different PCNs. 3 requests have been made for specific further insights within the dashboard, 1 has been concluded and deployed (SABA Overuse by age bracket) and 2 others are currently in development. An NHS educational body has also approached us to work in collaboration with them to deploy specific dashboard modules relating to areas of education for respiratory. [4 paragraphs unchanged]

Unchanged: Objective for processing, Processing activities, Expected output, Expected measurable benefits.

Objective for processing

BACKGROUND:

1. Comprehension and quantification of the prescribing trends across NHS England primary Care.

2. Through robust research, to not only add to the body of healthcare knowledge but reveal key prescribing trends and patterns over time in NHS prescribing activity.

3. Application of data to identify key prescribing improvements in terms of the alignment to national benchmarks and consistency of prescribing.

4. Provide solutions to support commissioning, analytical support, and outcomes analytics for NHS organisations, ranging from NHS England to regional teams.

The intention of the processing is to:

· Achieve widespread benefits to healthcare, including changes to patient care, reduced cost burden and uptake and monitoring of current health policies.

· Contribution of the already existing knowledge within the medical community to ignite further research into improving patient care.

• NHS Trusts

• Integrated Care Systems/Boards (ICSs/ICBs)

• Sustainability and Transformation Partnerships (STPs)

• Primacy Care Teams (including GPs / Nurses)

• Pharmaceutical companies

• Medical Device companies

Expected User Type – Private

Expected User Type – NHS

INTERVIEWS

• What therapy areas would be of interest to receive further analysis on ?

• How they would use this information?

• How the information would be used to benefit the health and social care sector?

• How the information would benefit the patients within the health and social care sector?

The interviewees flagged that the best delivery formats for the analysis would be:

• A secure web based dashboard for each therapy area

• An annual report for each therapy area that showcases headlines of the dashboard

NeoHealthHub Limited agreed with the interviewees that the therapy areas with the broadest potential benefit for the analysis would be:

• Asthma and COPD (respiratory)

• Diabetes

• Heart Failure

• Insomnia (with a focus on addictive medicines)

Although the focus will remain on the above areas, NeoHealthHub will remain reactive to NHS priorities with potential analysis in other areas, for example:

HRT therapy, Opioids, Anti Depressants & Obesity.

Unlimited access will be granted to any user from the NHS or a registered healthcare charity free of charge.

The following pseudonymised NHS England data is requested:

DATA MINIMISATION:

Data will be limited to the latest available and historic data over a five year period. Access to this fixed data period will be maintained within the SDE throughout the Data Sharing Agreement period. The data will be minimised further for each project of work by focusing on specific medicines within the dataset. Analysis will be minimised within the Secure Data Environment (SDE). The minimisation per use will be reviewed and approved by the Data Controller’s Managing Director & Director of Information Technology.

CONTROLLERSHIP

NeoHealthHub Limited is the controller as the organisation responsible for determining the purpose and means of the processing. For each project undertaken, NeoHealthHub will seek external review by a current member of the NHS (NeoHealthHub Limited have several NHS colleagues working with the organisation on a temporary contract basis. NHH Ltd consult this member when there is a new project and whether the project aligns with a wider piece of work . The aim is to make sure there is a legitimate purpose and benefit to access this tool for the NHS) who holds a relevant position (suggested to be a position within medicines optimisation) to ascertain the relevance of the project and the balance of benefit to the health and social care sector, patients and the commercial benefit to the private sector. Any private sector procuring access to the outputs will need to agree that the outputs will not be used for promoting or marketing of their products.

NeoHealthHub Limited is self-funding this work through the company's main core income stream which is subscription fees paid by pharmaceutical and healthcare companies.

LAWFUL BASIS

The lawful basis for processing personal data under the UK GDPR is:

The lawful basis for processing special category data under the UK GDPR is:

Expected output

The expected outputs of the processing will be:

• Monthly updated dashboards accessed by the NHS selected Charities and vetted private sector employees.

• Annual therapy area reports showcasing headlines from the dashboards developed

• Aggregated data tabulation provision in combination to retrospective studies.

The outputs will be communicated to relevant recipients through the NeoHealthHub Limited's portal being developed solely for this purpose. Clients to the service will be provided access to a secure online portal containing the dashboards produced by this data processing. With the first dashboard (Respiratory phase 1) now being live, it is expected that further dashboards will continue to be released every 2 months. Our respiratory annual report is now going through finalreview and Diabetes annual report will also follow in the next 2 months. Production of any retrospective studies will be within the 2 year agreement proposed but publication timescales are unknown.

Benefits reported

We currently have just under 30 NHS users with 12 ICBs being represented along with 5 different PCNs. 3 requests have been made for specific further insights within the dashboard, 1 has been concluded and deployed (SABA Overuse by age bracket) and 2 others are currently in development.

An NHS educational body has also approached us to work in collaboration with them to deploy specific dashboard modules relating to areas of education for respiratory.

Successful application for a grant alongside Kings College London and Menopause UK to utilise the data in a publication titled 'Understanding Cardiovascular Risk in High-Risk Women: exploring new opportunities to improve outcomes with menopause hormone therapy'. This project is ongoing and will conclude June 2025. Research will contribute to improving health equity by:

1. Highlighting inequities in menopause hormone therapy (MHT) prescribing

2. Exploring reasons for differences in MHT prescribing for underserved women

Final draft of our Respiratory Annual Review is now in final review and will be proactively made available free of charge to NHS medicines optimisation teams primarily and anyone with an NHS email address requesting access.

DARS-NIC-692602-Q6P4F-v1.3 27 June 2024 to 25 July 2024

Title: Data modelling and analytics
Commercial: Yes
Sublicensing: No
Datasets: 1
Files released: 0

Datasets: Medicines dispensed in Primary Care (NHSBSA data)

What changed from DARS-NIC-692602-Q6P4F-v0.5

Text removed is ~~struck through~~; text added is underlined. Unchanged paragraphs are summarised rather than repeated.

Fields changed from DARS-NIC-692602-Q6P4F-v0.5
Field	Was	Became
Start date	~~2024-01-15~~	2024-06-27
End date	~~2024-07-07~~	2024-07-25

Objective for processing

[38 paragraphs unchanged] ~~Other areas of note were:~~ Although the focus will remain on the above areas, NeoHealthHub will remain reactive to NHS priorities with potential analysis in other areas, for example: HRT therapy, Opioids, Anti ~~Depressants, Lipid Regulators~~ Depressants & ~~General Polypharmacy.~~ Obesity. [16 paragraphs unchanged]

Processing activities

[14 paragraphs unchanged] When processing data for insights and analysis NeoHealthHub Limited will ensure all [5 words unchanged] user are aggregated and small number double suppressed format in-line with NHS ~~Digital's~~ England's analysis guide. [4 paragraphs unchanged]

Expected output

[3 paragraphs unchanged] • Aggregated data tabulation provision in combination to retrospective studies. [1 paragraph unchanged] The outputs will be communicated to relevant recipients through the NeoHealthHub Limited's [16 words unchanged] a secure online portal containing the dashboards produced by this data processing. ~~Initial outputs are~~ With the first dashboard (Respiratory phase 1) now being live, it is expected that further dashboards will continue to be ~~produced between 1 to~~ released every 2 ~~months from initial data access. The NeoHealthHub Limited team~~ months. Our respiratory annual report is now going through finalreview and Diabetes annual report will ~~update~~ also follow in the ~~portal monthly. The first annual therapy area reports~~ next 2 months. Production of any retrospective studies will be within the 2 year agreement proposed but publication timescales are ~~expected to be completed 3 months from initial data access.~~ unknown.

Expected measurable benefits

The service provision via secure access dashboards and annual headlines reports will [14 words unchanged] health care sector employees. NeoHealthHub intend to generate awareness of the dashboards ,annual reports and ~~annual reports~~ the potential to generate restrospective study publications initially to medicines optimisation personnel or individuals with medicines efficiencies as a [99 words unchanged] interventions. This will be a key principle behind our sharing of data. [59 paragraphs unchanged] Working with individuals from the NHS, NeoHealthHub have aligned the proposed outputs [99 words unchanged] of people will suffer from Insomnia at some point in there life. Although the core focus of our efforts will be centered on the above therapy areas, NeoHealthHub want to remain flexible to the priorities of the NHS and will therefore reserve a smaller percentage of time to review the potential of outputs within other therapy areas. It is hoped that this approach will enable us to be agile when approached with needs in which is an ever changing treatment environment. [6 paragraphs unchanged]

Benefits reported

~~Yielded Benefits is not a requirement for new applications.~~ Phase 1 of our Respiratory Dashboard has been concluded and users are able to view interactive maps, dashboards and tables showing ICB and Sub ICB organisations. Registration and access to the site is available without charge to anyone with an NHS email address. Medicines Optimisation personnel will be able to make more informed decisions on Respiratory medicines optimisation project prioritisation. Our Insomnia Dashboard will be concluded by the end of June 2024 which will be available in a the same way. Successful application for a grant alongside Kings College London and Menopause UK to utilise the data in a publication titled 'Understanding Cardiovascular Risk in High-Risk Women: exploring new opportunities to improve outcomes with menopause hormone therapy'. This project is ongoing and will conclude June 2025. Research will contribute to improving health equity by: 1. Highlighting inequities in menopause hormone therapy (MHT) prescribing 2. Exploring reasons for differences in MHT prescribing for underserved women Final draft of our Respiratory Annual Review is now in final review and will be proactively made available free of charge to NHS medicines optimisation teams primarily and anyone with an NHS email address requesting access.

Objective for processing

BACKGROUND:

1. Comprehension and quantification of the prescribing trends across NHS England primary Care.

2. Through robust research, to not only add to the body of healthcare knowledge but reveal key prescribing trends and patterns over time in NHS prescribing activity.

3. Application of data to identify key prescribing improvements in terms of the alignment to national benchmarks and consistency of prescribing.

4. Provide solutions to support commissioning, analytical support, and outcomes analytics for NHS organisations, ranging from NHS England to regional teams.

The intention of the processing is to:

· Achieve widespread benefits to healthcare, including changes to patient care, reduced cost burden and uptake and monitoring of current health policies.

· Contribution of the already existing knowledge within the medical community to ignite further research into improving patient care.

• NHS Trusts

• Integrated Care Systems/Boards (ICSs/ICBs)

• Sustainability and Transformation Partnerships (STPs)

• Primacy Care Teams (including GPs / Nurses)

• Pharmaceutical companies

• Medical Device companies

Expected User Type – Private

Expected User Type – NHS

INTERVIEWS

• What therapy areas would be of interest to receive further analysis on ?

• How they would use this information?

• How the information would be used to benefit the health and social care sector?

• How the information would benefit the patients within the health and social care sector?

The interviewees flagged that the best delivery formats for the analysis would be:

• A secure web based dashboard for each therapy area

• An annual report for each therapy area that showcases headlines of the dashboard

NeoHealthHub Limited agreed with the interviewees that the therapy areas with the broadest potential benefit for the analysis would be:

• Asthma and COPD (respiratory)

• Diabetes

• Heart Failure

• Insomnia (with a focus on addictive medicines)

Although the focus will remain on the above areas, NeoHealthHub will remain reactive to NHS priorities with potential analysis in other areas, for example:

HRT therapy, Opioids, Anti Depressants & Obesity.

Unlimited access will be granted to any user from the NHS or a registered healthcare charity free of charge.

The following pseudonymised NHS England data is requested:

DATA MINIMISATION:

CONTROLLERSHIP

NeoHealthHub Limited is self-funding this work through the company's main core income stream which is subscription fees paid by pharmaceutical and healthcare companies.

LAWFUL BASIS

The lawful basis for processing personal data under the UK GDPR is:

The lawful basis for processing special category data under the UK GDPR is:

Expected output

The expected outputs of the processing will be:

• Monthly updated dashboards accessed by the NHS selected Charities and vetted private sector employees.

• Annual therapy area reports showcasing headlines from the dashboards developed

• Aggregated data tabulation provision in combination to retrospective studies.

The outputs will be communicated to relevant recipients through the NeoHealthHub Limited's portal being developed solely for this purpose. Clients to the service will be provided access to a secure online portal containing the dashboards produced by this data processing. With the first dashboard (Respiratory phase 1) now being live, it is expected that further dashboards will continue to be released every 2 months. Our respiratory annual report is now going through finalreview and Diabetes annual report will also follow in the next 2 months. Production of any retrospective studies will be within the 2 year agreement proposed but publication timescales are unknown.

Benefits reported

1. Highlighting inequities in menopause hormone therapy (MHT) prescribing

2. Exploring reasons for differences in MHT prescribing for underserved women

DARS-NIC-692602-Q6P4F-v0.5 15 January 2024 to 7 July 2024

Title: Data modelling and analytics
Commercial: Yes
Sublicensing: No
Datasets: 1
Files released: 0

Datasets: Medicines dispensed in Primary Care (NHSBSA data)

Objective for processing

BACKGROUND:

1. Comprehension and quantification of the prescribing trends across NHS England primary Care.

2. Through robust research, to not only add to the body of healthcare knowledge but reveal key prescribing trends and patterns over time in NHS prescribing activity.

3. Application of data to identify key prescribing improvements in terms of the alignment to national benchmarks and consistency of prescribing.

4. Provide solutions to support commissioning, analytical support, and outcomes analytics for NHS organisations, ranging from NHS England to regional teams.

The intention of the processing is to:

· Achieve widespread benefits to healthcare, including changes to patient care, reduced cost burden and uptake and monitoring of current health policies.

· Contribution of the already existing knowledge within the medical community to ignite further research into improving patient care.

• NHS Trusts

• Integrated Care Systems/Boards (ICSs/ICBs)

• Sustainability and Transformation Partnerships (STPs)

• Primacy Care Teams (including GPs / Nurses)

• Pharmaceutical companies

• Medical Device companies

Expected User Type – Private

Expected User Type – NHS

INTERVIEWS

• What therapy areas would be of interest to receive further analysis on ?

• How they would use this information?

• How the information would be used to benefit the health and social care sector?

• How the information would benefit the patients within the health and social care sector?

The interviewees flagged that the best delivery formats for the analysis would be:

• A secure web based dashboard for each therapy area

• An annual report for each therapy area that showcases headlines of the dashboard

NeoHealthHub Limited agreed with the interviewees that the therapy areas with the broadest potential benefit for the analysis would be:

• Asthma and COPD (respiratory)

• Diabetes

• Heart Failure

• Insomnia (with a focus on addictive medicines)

Other areas of note were:

HRT therapy, Opioids, Anti Depressants, Lipid Regulators & General Polypharmacy.

Unlimited access will be granted to any user from the NHS or a registered healthcare charity free of charge.

The following pseudonymised NHS England data is requested:

DATA MINIMISATION:

CONTROLLERSHIP

NeoHealthHub Limited is self-funding this work through the company's main core income stream which is subscription fees paid by pharmaceutical and healthcare companies.

LAWFUL BASIS

The lawful basis for processing personal data under the UK GDPR is:

The lawful basis for processing special category data under the UK GDPR is:

Expected output

The expected outputs of the processing will be:

• Monthly updated dashboards accessed by the NHS selected Charities and vetted private sector employees.

• Annual therapy area reports showcasing headlines from the dashboards developed

The outputs will be communicated to relevant recipients through the NeoHealthHub Limited's portal being developed solely for this purpose. Clients to the service will be provided access to a secure online portal containing the dashboards produced by this data processing. Initial outputs are expected to be produced between 1 to 2 months from initial data access. The NeoHealthHub Limited team will update the portal monthly. The first annual therapy area reports are expected to be completed 3 months from initial data access.

Benefits reported

Yielded Benefits is not a requirement for new applications.

Register history

When this agreement appeared in, or was edited in, each monthly edition of the register. Built by comparing every edition this site holds.

February 2024 — first listed.
1 version: DARS-NIC-692602-Q6P4F-v0.5
August 2024
2 versions added: DARS-NIC-692602-Q6P4F-v1.3, DARS-NIC-692602-Q6P4F-v2.2
December 2024
1 version added: DARS-NIC-692602-Q6P4F-v3.2
March 2025
1 version added: DARS-NIC-692602-Q6P4F-v4.4

Cite this page

NHS England (2026) Data Uses Register, September 2026 edition, agreement DARS-NIC-692602-Q6P4F, “Data modelling and analytics - Primary Care Prescribing and Primary Care Prescribing Impact on Secondary Care activity”. Read via NHS Data Access Explorer (unofficial), https://healthdatauses.uk/agreements/dars-nic-692602-q6p4f/ (accessed [date]).

This address stays the same, but the page is rebuilt with each monthly edition, so the citation names the edition it shows. Every edition's data is kept in the facts store.

Source: datausesregister_september2026.xlsx, September 2026 edition of the NHS England Data Uses Register. Search that workbook for DARS-NIC-692602-Q6P4F to see the original rows.